Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model [Seeking Alpha]
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says [Yahoo! Finance]
Ligand Pharmaceuticals (LGND) is now covered by Bank of America Corporation. They set a "buy" rating and a $244.00 price target on the stock.
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth [Yahoo! Finance]
Ligand to Participate in March Investor Conferences [Yahoo! Finance]